Analyst Price Target is $87.00
▲ +74.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Basilea Pharmaceutica in the last 3 months. The average price target is $87.00, with a high forecast of $87.00 and a low forecast of $87.00. The average price target represents a 74.00% upside from the last price of $50.00.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Basilea Pharmaceutica. This Buy consensus rating has held steady for over two years.
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.